1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Novartis Will Not Split Biosimilars From Sandoz As Part Of Review

Swiss Firm Focused On Carving Out Its Financials And Identifying Scope

 
• By Dean Rudge

Reporting Q4 and full-year earnings, Novartis told attendees to the company conference call that evaluating all options for its Sandoz business would take months yet, while making its position clear on Sandoz’ multi-billion-dollar biosimilars business.

Concept For Social Distancing And Self Isolating In Coronavirus Covid 19 Pandemic Crisis
Biosimilars will not be kept separate from Sandoz • Source: Alamy

Novartis expects it will take until the middle of the year to evaluate all potential options for its Sandoz business, amid an ongoing strategic review of the generics and biosimilars unit focused on carving out its financials and identifying the “perimeter” of Sandoz that would potentially be spun or sold.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.